Thermo Fisher Scientific EGFR Antibody Cocktail, Biotin

Applications

Tested Dilution

Publications

Western Blot (WB)

-

View 5 publications 5 publications

Immunohistochemistry (IHC)

-

View 1 publication 1 publication

Immunocytochemistry (ICC/IF)

-

View 4 publications 4 publications

Flow Cytometry (Flow)

-

View 1 publication 1 publication

ELISA (ELISA)

-

View 1 publication 1 publication

Immunoprecipitation (IP)

2 µg/mL

View 25 publications 25 publications

ChIP assay (ChIP)

-

View 1 publication 1 publication

Neutralization (Neu)

-

View 1 publication 1 publication

Product Specifications

Published species

Hamster, Human, Mouse, Non-human primate, Rat

Host/Isotype

Mouse / IgG2a

Class

Cocktail

Type

Antibody

Clone

528 + 199.12

Immunogen

Partially purified EGFR from A431 cells (clone 528) and extracellular domain of recombinant human EGFR protein (clone 199.12)

Conjugate

Biotin Biotin Biotin

Form

Liquid

Concentration

0.2 mg/mL

Storage conditions

4° C

Shipping conditions

Wet ice

RRID

AB_10985564

Product Specific Information

MA5-13694 targets Epidermal Growth Factor Receptor in IP applications and shows reactivity with Human samples.

The MA5-13694 immunogen is partially purified EGFR from A431 cells (clone 528) and extracellular domain of recombinant human EGFR protein (clone 199.12).

Target Information

EGFR, epidermal growth factor receptor, is a receptor tyrosine kinases that signals in response to various growth factors. Overexpression has been linked to numerous types of cancer and EGFR is the target of both biological and small molecular therapeutics. EGFR is encoded by the EGFR gene located on chromosome 7 in humans. EGFR belongs to the HER/ERbB family of proteins that includes three other receptor tyrosine kinases, ERbB2, ERbB3, ERbB4. EGFR is a transmembrane receptor and binding of its cognate ligands such as EGF (Epidermal Growth Factor) and TGF alpha (Transforming Growth Factor alpha) to the extracellular domain leads to EGFR dimerization followed by autophosphorylation of the tyrosine residues in the cytoplasmic domain. Overexpression is observed in tumors of the head and neck, brain, bladder, stomach, breast, lung, endometrium, cervix, vulva, ovary, esophagus, stomach and in squamous cell carcinoma.

For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.